TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Abpro Holdings ( (ABP) ) has issued an update.
On March 25, 2025, Abpro Holdings announced that it will present preclinical data for its investigational drug ABP-102/CT-P72 at the American Association for Cancer Research Annual Meeting 2025. This drug, developed in collaboration with Celltrion, is a novel HER2 x CD3 T-cell engager aimed at treating various HER2+ cancers by selectively targeting tumor cells while minimizing effects on normal tissues. The announcement highlights Abpro’s strategic partnership with Celltrion and reinforces its position in the biotechnology industry, potentially impacting its market focus and stakeholder interests.
More about Abpro Holdings
Abpro Holdings, Inc. is a biotechnology company focused on developing next-generation antibody therapies for severe and life-threatening diseases. The company is advancing treatments for HER2+ cancers, non-HER2+ gastric and liver cancer, and eye conditions like wet age-related macular degeneration and diabetic macular edema, utilizing its proprietary DiversImmune® platform. Abpro is based in Woburn, Massachusetts.
YTD Price Performance: -72.48%
Average Trading Volume: 142,979
Technical Sentiment Signal: Buy
Current Market Cap: $22.45M
See more insights into ABP stock on TipRanks’ Stock Analysis page.